Patents by Inventor Yongzhang Luo
Yongzhang Luo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230390364Abstract: Provided is the use of human serum albumin in the manufacturing of a drug for treating diabetes, obesity, atherosclerosis, Alzheimer's disease, Parkinson's disease and other diseases. In a preferred embodiment, the human serum albumin is the recombinantly prepared young and uninjured human serum albumin, and has achieved excellent effects in reducing the blood sugar level of a diabetic patient.Type: ApplicationFiled: November 1, 2021Publication date: December 7, 2023Applicant: Shenzhen Protgen Ltd.Inventors: Yongzhang Luo, Yan Fu, Hongyi Liu, Anji Ju, Jiaze Tang, Yi Jiang, Boyuan Ma, Xiaoqin Jiang, Yu Feng, Guodong Chang, Hui Li
-
Publication number: 20230265166Abstract: Provided is a method of extending lifespan and/or anti-aging in a subject, comprising the step of administering to the subject an effective amount of a preparation of young and undamaged human serum albumin (HSA), wherein the preparation exhibits at least one, preferably all, of the following properties: (1) higher ratio of free thiol in Cys-34 residue, (2) lower level of advanced glycation end-product (AGE), (3) lower level of carbonylation, and (4) lower level of homocysteinylation, as compared to an endogenous HSA preparation obtained from said subject.Type: ApplicationFiled: August 11, 2021Publication date: August 24, 2023Inventors: Yongzhang Luo, Yan FU, Jiaze TANG, Anji JU, Boya LI, Yuanchao GONG, Shaosen ZHANG, Guodong CHANG, Hui LI
-
Publication number: 20230174644Abstract: The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules that specifically bind to nucleic acid molecules encoding Nucleolin. The present invention also discloses methods of screening for angiogenesis inhibitors which specifically interact with Nucleolin, and act as angiogenesis inhibitors in an analogous manner as Endostatin. In addition, the present invention discloses methods of inhibiting the proliferation of endothelial cells or angiogenesis of tumor by administering an anti-nucleolin antibody linked to a cytotoxic agent such as tumor necrosis factor alpha to the endothelial cells.Type: ApplicationFiled: July 6, 2022Publication date: June 8, 2023Applicants: Tsinghua University, PROTOGEN LTD.Inventors: Yongzhang LUO, Hubing SHI
-
Publication number: 20220409703Abstract: The present invention provides use of endostatin or a functional variant thereof in the preparation of a medicament for treating dietary obesity, non-alcoholic fatty liver disease, insulin resistance or glucose intolerance. In the embodiments of the present invention, the functional variant may be YH-16, mES, mYH-16, m003, m007, mZ101, or the like.Type: ApplicationFiled: July 20, 2022Publication date: December 29, 2022Inventors: Yongzhang LUO, Hui WANG, Hui LI, Xinan LU, Yan FU, Shunli ZHAN, Daifu ZHOU
-
Patent number: 11434288Abstract: The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules that specifically bind to nucleic acid molecules encoding Nucleolin. The present invention also discloses methods of screening for angiogenesis inhibitors which specifically interact with Nucleolin, and act as angiogenesis inhibitors in an analogous manner as Endostatin. In addition, the present invention discloses methods of inhibiting the proliferation of endothelial cells or angiogenesis of tumor by administering an anti-nucleolin antibody linked to a cytotoxic agent such as tumor necrosis factor alpha to the endothelial cells.Type: GrantFiled: March 26, 2009Date of Patent: September 6, 2022Assignees: Protogen Ltd., Tsinghua UniversityInventors: Yongzhang Luo, Hubing Shi
-
Publication number: 20210085754Abstract: Provided is a mutant of an endostatin. The mutant has improved ATPase activity and improved activity of inhibiting angiogenesis and inhibiting tumors. Further provided is use of the mutant in treatment of angiogenesis related diseases such as tumors.Type: ApplicationFiled: September 28, 2020Publication date: March 25, 2021Applicants: TSINGHUA UNIVERSITY, BEIJING PROTGEN LTD.Inventors: Yongzhang LUO, Peng LIU, Xinan LU
-
Patent number: 10869910Abstract: Provided is a mutant of an endostatin. The mutant has improved ATPase activity and improved activity of inhibiting angiogenesis and inhibiting tumors. Further provided is use of the mutant in treatment of angiogenesis related diseases such as tumors.Type: GrantFiled: February 14, 2016Date of Patent: December 22, 2020Assignees: Tsinghua University, BEIJING PROTGEN LTD.Inventors: Yongzhang Luo, Peng Liu, Xinan Lu
-
Publication number: 20200237796Abstract: A method for treating a tumor or cancer by means of a treatment scheme of using endostatin in combination with induction of DNA double-strand breaks, and a medication. The method and composition are used for treating a tumor or cancer related to loss of p53 function, or a tumor or cancer occurring when p53 function is normal.Type: ApplicationFiled: July 27, 2018Publication date: July 30, 2020Inventors: Yongzhang LUO, Lin JIA, Guodong CHANG
-
Patent number: 10647968Abstract: The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.Type: GrantFiled: September 10, 2012Date of Patent: May 12, 2020Assignees: Tsinghua University, Beijing Protgen Ltd.Inventors: Yongzhang Luo, Peng Liu, Xinan Lu, Yang Chen, Yan Fu, Guodong Chang, Daifu Zhou
-
Publication number: 20180360922Abstract: The present invention discloses an anti-tumor conjugate and pharmaceutical composition or kits comprising the conjugate, as well as a method of producing the anti-tumor conjugate. The anti-tumor conjugate of the present invention is metabolically stable in vivo, and is ultimately available for the treatment of tumors and production of anti-tumor medicaments.Type: ApplicationFiled: July 2, 2018Publication date: December 20, 2018Applicants: TSINGHUA UNIVERSITY, PROTGEN LTD.Inventors: Yongzhang LUO, Qing HAN, Qingxin LEI, Guodong CHANG, Yan FU
-
Patent number: 10054590Abstract: The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors or cancer suppressors, which function in a manner that is analogous to endostatin. The invention is based upon the discovery that nucleolin is specifically expressed on lymphangiogenic vessels and functions as a specific receptor for endostatin, and thus is involved in the signal transduction pathway of endostatin as an anti-lymphangiogenesis inhibitor. The present invention also discloses that cell surface nucleolin on lymphatic endothelial cells is a biomarker for lymphangiogenic vessels, which could be used for the prediction of tumor metastasis.Type: GrantFiled: August 8, 2013Date of Patent: August 21, 2018Assignees: Tsinghua University, Protgen Ltd.Inventors: Yongzhang Luo, Wei Zhuo, Yan Fu, Guodong Chang
-
Publication number: 20180200337Abstract: Provided is amutant of an endostatin. The mutant has improved ATPase activity and improved activity of inhibiting angiogenesis and inhibiting tumors. Further provided is use of the mutant in treatment of angiogenesis related diseases such as tumors.Type: ApplicationFiled: February 14, 2016Publication date: July 19, 2018Applicants: Tsinghua University, BEIJING PROTGEN LTD.Inventors: Yongzhang LUO, Peng LIU, Xinan LU
-
Publication number: 20180094051Abstract: The present invention provides a method for inhibiting lymphangiogenesis in a subject, comprising administering a therapeutically effective amount of a CXCR4 inhibitor and/or a CXCL12 inhibitor to the subject. The invention further provides a method for inhibiting tumor lymphatic metastasis in a cancer patient, comprising administering to the subject (a) a therapeutically effective amount of a CXCR4 inhibitor and/or a CXCL12 inhibitor, in combination with (b) a therapeutically effective amount of a VEGF-C inhibitor and/or a VEGF-D inhibitor and/or a VEGFR-3 inhibitor.Type: ApplicationFiled: December 14, 2017Publication date: April 5, 2018Inventors: Yongzhang LUO, Wei ZHUO, Lin JIA, Yan FU, Guodong CHANG
-
Publication number: 20180015148Abstract: The present invention provides use of endostatin or a functional variant thereof in the preparation of a medicament for treating dietary obesity, non-alcoholic fatty liver disease, insulin resistance or glucose intolerance. In the embodiments of the present invention, the functional variant may be YH-16, mES, mYH-16, m003, m007, mZ101, or the like.Type: ApplicationFiled: November 3, 2015Publication date: January 18, 2018Applicants: TSINGHUA UNIVERSITY, BEIJING PROTGEN LTD.Inventors: Yongzhang LUO, Hui WANG, Hui LI, Xinan LU, Yan FU, Shunli ZHAN, Daifu ZHOU
-
Patent number: 9815906Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90? having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.Type: GrantFiled: February 13, 2015Date of Patent: November 14, 2017Assignees: TSINGHUA UNIVERSITY, PROTGEN LTD.Inventors: Yongzhang Luo, Xiaomin Song, Xiaofeng Wang, Wei Zhuo, Guodong Chang, Yan Fu
-
Publication number: 20160178633Abstract: A method of determining whether a subject has cancer or has a risk of getting cancer comprises: detecting the concentration of Hsp90a in a blood sample of the subject; and if the concentration reaches or exceeds a preset threshold value, determining that the subject has cancer or has a risk of getting cancer, where the threshold value is selected from a range from 50 ng/ml to 120 ng/ml; for example, the threshold value may be 50, 53, 56, 62, 63, 64, 67, 72, 82, 85 or 117 ng/ml, and a numerical value within the ±15% range of the threshold value is regarded having equivalent significance for determination.Type: ApplicationFiled: June 27, 2014Publication date: June 23, 2016Applicants: TSINGHUA UNIVERSITY, YANTAI PROTGEN BIOTECHNOLOGY DEVELOPMENT CO., LTD., BEIJING PROTGEN LTD.Inventors: Yongzhang Luo, Dawei Cui, Yan Fu, Fei Wu, Xiaomin Song, Michuan Li, Guodong Chang, Chuntao Lu
-
Patent number: 9364493Abstract: The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.Type: GrantFiled: March 28, 2012Date of Patent: June 14, 2016Assignees: Tsinghua University, Beijing Protgen LTD.Inventors: Yongzhang Luo, Yang Chen, Yan Fu, Lin Jia, Guodong Chang
-
Patent number: 9145452Abstract: The invention provides the uses of fibrinogen-420 or alpha EC domain thereof, for inhibiting protein aggregation, refolding the denatured proteins, manufacturing drugs for prevention and/or treatment of protein misfolding diseases, resisting protein denaturation, and detecting the quality of protein products. The invention also provides the drugs for prevention and/or treatment of protein misfolding diseases or protein denatured disease, and the protein stabilizer. The active ingredient of the said drugs and stabilizer is fibrinogen-420 or alpha EC domain thereof.Type: GrantFiled: September 6, 2013Date of Patent: September 29, 2015Assignee: Tsinghua UniversityInventors: Yongzhang Luo, Huadong Tang, Yan Fu
-
Publication number: 20150259432Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90? having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.Type: ApplicationFiled: February 13, 2015Publication date: September 17, 2015Applicants: TSINGHUA UNIVERSITY, PROTGEN LTD.Inventors: Yongzhang LUO, Xiaomin SONG, Xiaofeng WANG, Wei ZHUO, Guodong CHANG, Yan FU
-
Publication number: 20150197733Abstract: The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.Type: ApplicationFiled: September 10, 2012Publication date: July 16, 2015Applicants: BEIJING PROTGEN LTD., TSINGHUA UNIVERSITYInventors: Yongzhang Luo, Peng Liu, Xinan Lu, Yang Chen, Yan Fu, Guodong Chang, Daifu Zhou